Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 4.

Tan, Daniel S-W, Leighl, Natasha B., Riely, Gregory J., Yang, James C-H, Sequist, Lecia, V, Wolf, Juergen, Seto, Takashi, Felip, Enriqueta, Aix, Santiago P., Jonnaert, Maud, Pan, Chun, Tan, Eugene Y., Ko, Jinnie, Moody, Susan E. and Kim, Dong-Wan (2020). Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Resp. Med., 8 (6). S. 561 - 573. OXFORD: ELSEVIER SCI LTD. ISSN 2213-2600

Tan, Daniel S. W., Kim, Sang-We, Aix, Santiago Ponce, Sequist, Lecia, V, Smit, Egbert F., Yang, James C. H., Hida, Toyoaki, Toyozawa, Ryo, Felip, Enriqueta, Wolf, Juergen, Grohe, Christian, Leighl, Natasha B., Riely, Gregory, Cui, Xiaoming, Zou, Mike, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2022). Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur. J. Cancer, 172. S. 276 - 287. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Tan, Daniel Shao-Weng, Leighl, Natasha B., Yang, James Chih-Hsin, Riely, Gregory J., Sequist, Lecia, V, Toyozawa, Ryo, Wolf, Juergen, Felip, Enriqueta, Kim, Sang-We, Aix, Santiago Ponce, Smit, Egbert F., Hida, Toyoaki, Grohe, Christian, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica and Kim, Dong-Wan (2020). Nazartinib (EGF816) in patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Tan, Daniel Shao-Weng, Yang, James Chih-Hsin, Leighl, Natasha B., Riely, Gregory J., Sequist, Lecia V., Felip, Enriqueta, Seto, Takashi, Wolf, Juergen, Moody, Susan Elizabeth, Adams, Kenneth, Schmitz, Shu-Fang Hsu, Tan, Eugene Y. and Kim, Dong-Wan (2016). Updated results of a phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Tue Nov 26 04:11:07 2024 CET.